Biopharma | February 24, 2026
ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
If approved, DTX401 would be the first treatment to address the disease at its root cause
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership
Subscribe To Our Newsletter & Stay Updated
